SBIR/STTR Research Award
Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes.
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Mycosynthetix, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JEPXCJLSMLS3
- Solicitation number
- PA12-088
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Title: Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes Project Summary/Abstract It is estimated that over 2 billion people worldwide are suffering from complications due to infections withsoil transmitted helminthes (STHs), but very little research is being conducted by human health pharmaceutical companies. In the USA, it is estimated that in distressed areas of poverty, just under 4 million people harbor undiagnosed STH infections. STH infections typically affect those living in poverty and underrepresented minority populations. Increased immigration, international travel and US soldiers returning from STH endemic countries are bringing undiagnosed helminth infections with them. There is an urgent need for new anti-parasitic agents for treating human gastrointestinal diseases caused by the STHs such as hookworm, ascarid, whipworm and strongyloides. Current treatment is by anthelmintics, which were derived from veterinary medicine rathe
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Fungal Metabolites Fuel Drug Discovery for Pathogenic Free-Living Amoebae
- Production of the organic herbicide Mevalocidin by fungi
- New Tuberculosis Antibiotics from Filamentous Fungi
- Novel Broad/Narrow-Spectrum Antibiotics Against Bacteria
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
5 SBIR/STTR records share this UEI (2004–2016). Reported award amounts total $802,392. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, Department of Agriculture